Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Management
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Tag: AsiDNA™

Onxeo to Present New Preclinical Data at AACR 2021

04/08/202104/08/2021

Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]

Boursorama – Judith Greciet, Onxeo : «AsiDNA could open a new paradigm in cancer treatment»

06/17/202012/02/2020

  Read the interview  

Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results

11/09/202011/09/2020

The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]

Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors

10/22/202010/22/2020

This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]

Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

10/21/202010/21/2020

Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]

Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States

09/03/202009/03/2020

This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]

Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer

08/27/202008/27/2020

DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]

Onxeo Announces Approval of the REVocan Study By Regulatory Authorities

05/29/202007/09/2020

The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]

New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020

06/22/202006/19/2020

Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells   […]

BFM Business Intégrale Bourse : Onxeo, Company of the Day

06/10/202006/11/2020

  Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]

Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi

05/19/202005/19/2020

Paris (France), Mai 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology

11/13/201903/13/2020

In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]

Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer

01/29/202003/13/2020

The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to […]

Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment

11/04/201911/05/2019

Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]

Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

10/15/201910/16/2019

Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]

Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform

10/14/201910/16/2019

This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]

Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy

09/18/201910/16/2019

  Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]

Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor

04/24/201810/04/2019

First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted […]

Onxeo Strengthens AsiDNA™ Patent Protection in Europe

11/29/201610/03/2019

Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence […]

Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration

07/05/201710/03/2019

Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor Paris (France), July 05 […]

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat

09/28/201710/03/2019

Results demonstrate a very strong synergistic effect between AsiDNA™,  first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) […]

Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

10/02/201710/03/2019

2 OCT., 2017 PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018 In parallel, the Company advances its […]

Onxeo Establishes Scientific Advisory Board with International Experts in DNA-targeting

11/28/201709/10/2019

Professor Tomas Lindahl, DNA Repair Pioneer and 2015 Nobel Prize laureate, will serve as Chair of the Scientific Advisory Board […]

Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNA™, a First-In-Class DNA Damage Response Inhibitor

11/05/201809/05/2019

Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with […]

Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors

05/28/201909/04/2019

Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced […]

Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA

06/27/201609/04/2019

Near- and mid term expected milestones  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the […]

Onxeo receives USPTO Notice of Allowance for key AsiDNA™ patent, extending IP protection in the U.S. until 2031

07/04/201609/04/2019

Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair […]

Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

09/07/201609/04/2019

Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative […]

The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology

12/08/201609/04/2019

Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class […]

Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future

01/31/201709/04/2019

The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), […]

Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.

02/13/201709/04/2019

New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™  Paris (France), February 13, 2017 […]

Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting

03/21/201709/04/2019

Preclinical studies of AsiDNA™, Livatag® and Beleodaq® Paris (France), March 21, 2017 – 6 pm CET – Onxeo S.A. (Euronext […]

Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent

01/25/201809/04/2019

Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031 Composition of matter patent […]

Onxeo to Present Results of Two Studies Highlighting Potential of AsiDNA™ as Anti-Cancer Treatment at 2018 AACR Annual Meeting

03/15/201809/04/2019

Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors

07/12/201809/04/2019

AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model […]

Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019

10/18/201809/04/2019

Paris, October 18, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology […]

Onxeo receives EPO Intent-to-Grant Notice for new patent protecting AsiDNA™ in combination with any PARP inhibitor

12/18/201809/04/2019

Combination patent to be granted in Europe until 2036   Paris (France), December 18, 2018 – 8.30 pm CET – […]

Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor

01/03/201909/04/2019

Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical […]

Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting

02/13/201909/04/2019

Paris (France), February 13, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting

03/25/201909/04/2019

Paris (France), March 25, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy

05/06/201909/04/2019

DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in […]

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

185 Alewife Brook Parkway
Suite 210, Cambridge, MA 02138
(617) 648-8674

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2023 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress